Daclatasvir, sold under the trade name Daklinza, is a medication used in combination with other medications to treat hepatitis C (HCV). The other medications used in combination include sofosbuvir, ribavirin, and interferon, vary depending on the virus type and whether the person has cirrhosis. It is taken by mouth once a day.

Common side effects with sofosbuvir and daclatasvir include headache, feeling tired, and nausea. With daclatasvir, sofosbuvir, and ribavirin the most common side effects are headache, feeling tired, nausea, and red blood cell breakdown. It should not be used with St. John’s wort, rifampin, or carbamazepine. It works by inhibiting the HCV protein NS5A.

Daclatasvir was approved for use in the European Union in 2014, and the United States and India in 2015. It is on the World Health Organization’s List of Essential Medicines.

The brand Daklinza is being withdrawn by Bristol Myers Squibb (BMS) in various countries and BMS will let the patents lapse in those countries.

MyDekla 60 mg (Daclatasvir) is a direct-acting antiviral (DAA) inhibitor drug specified for patients with chronic Hepatitis C viral (HCV) infection with genotype 1 or 3. After entering the system, daclatasvir starts its action by blocking the activities of a special protein (NS5A) responsible for multiplication (RNA replication and virion assembly) of viral cells.

MyDekla 60 mg (Daclatasvir) is taken along with other antiviral medications (sofosbuvir/ribavirin) used for HCV infection. Combining these therapies, assist in attaining a sustained virologic response (SAR) after 12 weeks of daily therapy.